Introducing hdac-targeting radiopharmaceuticals for glioblastoma imaging and therapy

HIGHLIGHTS

• who: Liesbeth Everix et al. from the Molecular Imaging Center Antwerp (MICA), University of Antwerp, Antwerpen, Belgium Cape Town, South Africa have published the article: Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy, in the Journal: Pharmaceuticals 2023, 227 of /2023/

SUMMARY

Glioblastoma multiforme (GB) is the most malignant tumor in the central nervous system (CNS). Due to their pleiotropic effects on, e_g, DNA repair, cell proliferation, differentiation, apoptosis and senescence, they have gained a lot of attention in the last decade as anti-cancer agents. HDACi valproic acid (valproate, VPA, Depakene . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.